Chongqing Modern Industry Research Institute conducts research on the Maikekang Biological Innovation Vaccine Production Transformation Platform

2024-05-19 11:14
On the morning of May 19th, representatives from Chongqing Modern Industry Research Institute conducted research on the Shanghai Innovation Vaccine Transfer Platform of MaxvaxBiotechnology. Mr. Zou Linkun, Party Secretary and Chairman of Lingang Fengxian Company, and Mr. Liang Jian, Director of Strategic Development and Business Management Department of Lingang Group, accompanied them.

Jin Yi, Deputy General Manager of Maikokang Biotechnology, introduced the company's development history, new adjuvants to solve the bottleneck problem of innovative vaccines, recombinant protein technology production platforms, and the company's strategic planning layout in the Lingang New Area to the research group. The research team fully affirmed the technological research and clinical promotion capabilities of Maikekang Biotechnology, and highly praised the ability of the innovative vaccine production platform to achieve sub production and landing.


微信截图_20240614100813.png


share
WeChat
Facebook
X
LinkedIn
Group Information
Prev Financing Progress | MAXVAX Biotechnology has completed its Series C financing, with a total of over 600 million yuan raised in Series C funding
Next The kickoff meeting for the Phase II clinical trial of the Meikokang Biological Recombinant Herpes Zoster Vaccine was successfully held
Phone
+86-21-68403318
QQ
1905311766
WeChet
WeChet
Scan Code
On-Line
Submit